Published in Br J Clin Pharmacol on July 01, 2014
Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers. Eur J Clin Pharmacol (2015) 0.78
Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Des Devel Ther (2015) 0.75
CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J (2016) 0.75
Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol (2016) 0.75
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed (2005) 6.36
The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia (1997) 5.31
Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis (2007) 5.06
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet (2009) 2.37
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ (2003) 2.18
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry (2004) 2.09
Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol (1993) 1.79
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet (2009) 1.73
Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol (1993) 1.66
Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol (1998) 1.53
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther (2006) 1.49
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos (2007) 1.40
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics (2011) 1.29
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics (2008) 1.27
Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett (1996) 1.20
Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol (1998) 1.19
In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med (2007) 1.09
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics (2009) 1.05
Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther (2009) 1.05
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit (2008) 1.04
The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol (1999) 1.04
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol (2006) 0.95
Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet Genomics (2011) 0.95
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit (2008) 0.95
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol (2005) 0.94
Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm (1997) 0.92
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology (2009) 0.92
Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol (1998) 0.88
Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res (2007) 0.88
Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol (1998) 0.86
Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clin Neuropharmacol (2010) 0.86
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol (2011) 0.84
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol (2010) 0.80
Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring. Ther Drug Monit (2011) 0.77
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS Med (2011) 2.49
Reducing stigma and discrimination against older people with mental disorders: a technical consensus statement. Int J Geriatr Psychiatry (2003) 2.35
Are circulating endothelial-derived and platelet-derived microparticles a pathogenic factor in the cisplatin-induced stroke? Stroke (2007) 2.17
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis (2012) 2.11
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res (2004) 1.95
Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry (2002) 1.88
Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch Intern Med (2010) 1.87
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics (2009) 1.79
Cortical microinfarcts and demyelination significantly affect cognition in brain aging. Stroke (2004) 1.74
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (2006) 1.61
Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. PLoS One (2011) 1.58
Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? J Neurol Sci (2007) 1.52
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther (2006) 1.49
Symptom relief in the last week of life: is dementia always a limiting factor? J Am Geriatr Soc (2007) 1.48
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics (2010) 1.46
Distinction between perceptual and attentional processing in working memory tasks: a study of phase-locked and induced oscillatory brain dynamics. J Cogn Neurosci (2007) 1.45
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther (2005) 1.45
Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain (2007) 1.44
Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol (2012) 1.44
Effect of mild endurance exercise training and pravastatin on peripheral vasodilatation of forearm resistance vessels in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil (2005) 1.40
Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry (2015) 1.40
Ascertaining late-life depressive symptoms in Europe: an evaluation of the survey version of the EURO-D scale in 10 nations. The SHARE project. Int J Methods Psychiatr Res (2008) 1.27
Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke (2005) 1.26
In vivo over-expression of interleukin-10 increases resistance to focal brain ischemia in mice. J Neurochem (2009) 1.23
Von Economo neurons in autism: a stereologic study of the frontoinsular cortex in children. Brain Res (2010) 1.20
Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J Comp Neurol (2003) 1.18
Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol (2006) 1.17
Neural substrates of cognitive and behavioral deficits in atypical Alzheimer's disease. Brain Res Rev (2006) 1.16
Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J Cereb Blood Flow Metab (2006) 1.16
Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (2003) 1.15
Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimers Dis (2010) 1.10
Pathological substrates of cognitive decline in Alzheimer's disease. Front Neurol Neurosci (2009) 1.10
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr HIV/AIDS Rep (2006) 1.10
Pain in severe dementia: self-assessment or observational scales? J Am Geriatr Soc (2006) 1.09
Resistance to cerebral ischemic injury in UCP2 knockout mice: evidence for a role of UCP2 as a regulator of mitochondrial glutathione levels. J Neurochem (2004) 1.07
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol (2005) 1.06
Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet (2013) 1.06
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics (2009) 1.05
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit (2008) 1.04
Stereologic estimates of total spinophilin-immunoreactive spine number in area 9 and the CA1 field: relationship with the progression of Alzheimer's disease. Neurobiol Aging (2007) 1.04
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol (2009) 1.03
Small vascular and Alzheimer disease-related pathologic determinants of dementia in the oldest-old. J Neuropathol Exp Neurol (2010) 1.03
Differential impact of lacunes and microvascular lesions on poststroke depression. Stroke (2009) 1.03
Neuroanatomical and neuropsychological features of euthymic patients with bipolar disorder. Am J Geriatr Psychiatry (2009) 1.02
Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer's disease. Neurobiol Aging (2005) 1.02
Assessing the role of cingulate cortex in bipolar disorder: neuropathological, structural and functional imaging data. Brain Res Rev (2008) 1.02
Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.01
Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening. Addict Behav (2005) 1.01
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit (2008) 1.01
Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease. J Neuropathol Exp Neurol (2003) 1.00
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res (2008) 0.99
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics (2008) 0.99
Cortical ubiquitin-positive inclusions in frontotemporal dementia without motor neuron disease: a quantitative immunocytochemical study. Acta Neuropathol (2004) 0.99
Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol (2006) 0.98
Combined analysis of grey matter voxel-based morphometry and white matter tract-based spatial statistics in late-life bipolar disorder. J Psychiatry Neurosci (2011) 0.98
Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) (2005) 0.98
Stereologic analysis of hippocampal Alzheimer's disease pathology in the oldest-old: evidence for sparing of the entorhinal cortex and CA1 field. Exp Neurol (2005) 0.96
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry (2007) 0.96
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malar J (2013) 0.96
Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol (2002) 0.96
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother (2012) 0.95
Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiol Dis (2006) 0.95
A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol (2007) 0.95
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit (2008) 0.95
The impact of vascular burden on late-life depression. Brain Res Rev (2009) 0.94
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.93
Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals. Radiology (2014) 0.92
A genome-wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer disease. Eur J Hum Genet (2011) 0.92
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet Genomics (2013) 0.92
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol (2002) 0.92
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol (2005) 0.92
In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology (2007) 0.92
Decreased pyramidal neuron size in Brodmann areas 44 and 45 in patients with autism. Acta Neuropathol (2012) 0.91
Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin Pharmacol Ther (2004) 0.91
Cerebral microhemorrhage and iron deposition in mild cognitive impairment: susceptibility-weighted MR imaging assessment. Radiology (2010) 0.91
Early event-related potential changes during working memory activation predict rapid decline in mild cognitive impairment. J Gerontol A Biol Sci Med Sci (2005) 0.91
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir Ther (2012) 0.90
Conformation-specific spectroscopy and photodissociation of cold, protonated tyrosine and phenylalanine. J Am Chem Soc (2007) 0.90
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther (2006) 0.90
Early disturbances of gamma band dynamics in mild cognitive impairment. J Neural Transm (Vienna) (2010) 0.90
The neuroanatomical model of post-stroke depression: towards a change of focus? J Neurol Sci (2009) 0.90
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet (2013) 0.89
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol (2007) 0.89
Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE epsilon 4 carriers. Am J Med Genet B Neuropsychiatr Genet (2003) 0.89
Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol (2006) 0.89
A new electrophysiological index for working memory load in humans. Neuroreport (2003) 0.89
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother (2012) 0.89